Hyderabad, India and Princeton, NJ, USA. July 11, 2018— Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Hydroxychloroquine Sulfate Tablets USP, 200 mg, a therapeutic equivalent generic version of Plaquenil® (hydroxychloroquine sulfate) Tablets, in the U.S. market, approved by the U.S. Food and Drug Administration (USFDA).
The Plaquenil® brand and generic had U.S. sales of approximately $215 million MAT for the most recent twelve months ending in May 2018 according to IMS Health*.
Dr. Reddy’s Hydroxychloroquine Sulfate Tablets are available in 200 mg tablets in the bottle count sizes of 100 and 500.
Plaquenil® is a trademark of Concordia International Corp.
Your email address will not be published. Required fields are marked *
Notify me of follow-up comments by email.
Notify me of new posts by email.
Sign me up for the newsletter!
Thirty Three Cryptocurrencies Infographics
ADITYA SINGH RAJPUT TO JOIN ARBAAZ KHAN, SAKSHI PRADHAN, FREDDY DARUWALA FOR ZEE5’S NEXT WEB SERIES POISON!
FIVE FEET APART releases in India on March 29
Newly launched Domino’s Pizza in Bangladesh breaks the global record in the first week
Homewood Suites by Hilton Providence Downtown Opens
2014 The Global Indian New Network (TGINN)